ALIM Alimera Sciences Inc.

-0.04  -4%
Previous Close 0.96
Open 0.94
Price To Book -2.36
Market Cap 65291140
Shares 70,968,630
Volume 84,064
Short Ratio
Av. Daily Volume 106,893

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014
Diabetic macular edema

Latest News

  1. Alimera Sciences Announces Expansion of Leadership Team with Appointment of Samer Kaba, MD as Chief Medical Officer
  2. Alimera Sciences Announces Approval Received in the Mutual Recognition Procedure for New Indication for ILUVIEN(R) in Europe
  3. Alimera Sciences Announces Approval for ILUVIEN (R) in Kuwait
  4. Alimera Sciences Announces the Reimbursement of ILUVIEN(R) in France
  5. Edited Transcript of ALIM earnings conference call or presentation 19-Feb-19 2:00pm GMT
  6. Will Alimera Sciences (ALIM) Report Negative Q4 Earnings? What You Should Know
  7. Alimera Sciences, Inc. to Host Earnings Call
  8. Alimera Sciences Reports Record Fourth Quarter and 2018 Results
  9. Alimera Sciences Announces Approval for ILUVIEN(R) in Lebanon
  10. Alimera Sciences to Report Fourth Quarter and Full Year 2018 Results on February 18, 2019
  11. Eye implant is helping treat vision loss in diabetics
  12. Alimera Sciences Affirms Record 2018 Revenues
  13. What Type Of Shareholder Owns Alimera Sciences, Inc.’s (NASDAQ:ALIM)?
  14. Alimera Sciences Announces Pricing Approval For ILUVIEN(R) in the U.A.E.
  15. Alimera Sciences Appoints Rick Eiswirth as Chief Executive Officer
  16. Alimera Sciences Announces Canadian Regulatory Approval for ILUVIEN(R)
  17. Consolidated Research: 2018 Summary Expectations for Texas Instruments, Sino-Global Shipping America, Alimera Sciences, Sypris Solutions, JetPay, and Performant Financial — Fundamental Analysis, Key Performance Indications
  18. Edited Transcript of ALIM earnings conference call or presentation 6-Nov-18 2:00pm GMT
  19. Alimera Sciences to Present at Upcoming Investor Conferences
  20. Alimera Sciences (ALIM) Reports Q3 Loss, Tops Revenue Estimates